Article

NMR Structure of the FIV gp36 C-terminal Heptad Repeat and Membrane-Proximal External Region

Manuela Grimaldi 1,2, Michela Buonocore 1, Mario Scrima 1, Ilaria Stillitano 1, Gerardino D’Errico 3, Angelo Santoro 1, Giuseppina Amodio 4, Daniela Eletto 1, Antonio Gloria 2, Teresa Russo 2, Ornella Moltedo 1, Paolo Remondelli 4, Alessandra Tosco 1, Hans L. J. Wienk 5,6 and Anna Maria D’Ursi 1,*

1 Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 134, I-84084 Fisciano, Italy; magrimaldi@unisa.it (M.G.); mbuonocore@unisa.it (M.B.); mscrima@unisa.it (M.S.); istillitano@unisa.it (I.S.); asantoro@unisa.it (A.S.); daeletto@unisa.it (D.E.); moltedo@unisa.it (O.M.); tosco@unisa.it (A.T.)
2 Institute of Polymers, Composites and Biomaterials, National Research Council of Italy, V.le J.F. Kennedy 54 - Pad. 20 Mostra d’Oltremare, 80125 Naples, Italy; angloria@unina.it (A.G.); teresa.russo@unina.it (T.R.)
3 Department of Chemical Sciences, University of Naples Federico II, Monte S. Angelo, Via Cinthia, 80126 Naples, Italy; gerardino.derrico@unina.it
4 Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Via S. Allende, 84081 Baronissi (SA), Italy; gamodio@unisa.it (G.A.); premondelli@unisa.it (P.R.)
5 Department of Chemistry, NMR Spectroscopy, Bijvoet Center for Biomolecular Research, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands; h.l.j.wienk@uu.nl
6 Division of Biochemistry, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
* Correspondence: dusri@unisa.it; Tel.: +39-089969748

Received: 16 February 2020; Accepted: 13 March 2020; Published: 16 March 2020

Abstract: Feline immunodeficiency virus (FIV), a lentivirus causing an immunodeficiency syndrome in cats, represents a relevant model of pre-screening therapies for human immunodeficiency virus (HIV). The envelope glycoproteins gp36 in FIV and gp41 in HIV mediate the fusion of the virus with the host cell membrane. They have a common structural framework in the C-terminal region that includes a Trp-rich membrane-proximal external region (MPER) and a C-terminal heptad repeat (CHR). MPER is essential for the correct positioning of gp36 on the lipid membrane, whereas CHR is essential for the stabilization of the low-energy six-helical bundle (6HB) that is necessary for the fusion of the virus envelope with the cell membrane. Conformational data for gp36 are missing, and several aspects of the MPER structure of different lentiviruses are still debated. In the present work, we report the structural investigation of a gp36 construct that includes the MPER and part of the CHR domain (737-786 gp36 CHR–MPER). Using 2D and 3D homo and heteronuclear NMR spectra on 15N and 13C double-labelled samples, we solved the NMR structure in micelles composed of dodecyl phosphocholine (DPC) and sodium dodecyl sulfate (SDS) 90/10 M: M. The structure of 737-786 gp36 CHR–MPER is characterized by a helix–turn–helix motif, with a regular α-helix and a moderately flexible 3_10 helix, characterizing the CHR and the MPER domains, respectively. The two helices are linked by a flexible loop regulating their orientation at a ~43° angle. We investigated the positioning of 737-786 gp36 CHR–MPER on the lipid membrane using spin label-enhanced NMR and ESR spectroscopies. On a different scale, using confocal microscopy imaging, we studied the effect of 737-786 gp36 CHR–MPER on 1,2-dioleoyl-sn-glycero-3-phosphocholine/1,2-dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (DOPC/DOPG) multilamellar vesicles (MLVs). This effect results in membrane budding and tubulation that is reminiscent of a membrane-plasticizing role that is typical of MPER domains during the event in which the virus envelope merges with the host cell membrane.

Keywords: HIV; FIV; MPER; envelope glicoproteins; NMR
1. Introduction

Feline immunodeficiency virus (FIV) is a lentivirus infecting T lymphocytes in cats and causing an immunodeficiency syndrome, which is very similar to the one caused by HIV [1–4] in humans. The study of FIV and the design of molecules capable of preventing FIV infection in cats poses an important impulse on veterinary medicine to develop an effective FIV vaccine or therapy [5]. Furthermore, FIV represents a relevant model of pre-screening studies for HIV.

Lentiviruses enter host cells due to specific envelope glycoproteins that boost the interaction of the virus with the receptors on the host cell surface. Gp36 in FIV and gp41 in HIV catalyse virus envelope fusion with the respective host cell membranes. They show a common structural framework (Figure 1) [6–8] that includes the fusion peptide (FP), N-terminal heptad repeat (NHR), C-terminal heptad repeat (CHR) and membrane-proximal extracellular region (MPER). MPER is a hydrophobic, Trp-rich region (Figure 1) characterized by a strong membrane affinity. Virus entry is successful if NHR and CHR fold back to form a low-energy stable six-helical bundle (6HB) [9]; during this process, MPER plays an active role by correctly driving the virus membrane to assemble with the host cell membrane.

The design of molecules interfering with the formation of the 6HB or inhibiting the correct positioning of MPER on the membrane is a strategy currently being used to design new antiviral compounds acting as inhibitors of virus entry.

Peptides corresponding to fragments of gp41 or gp36 have been exploited as antiviral drugs or vaccines [10–12]; given the immunogenic potential of gp41 MPER, peptides from this region have been considered to develop anti-HIV vaccines [13–16], while peptides derived from gp36 MPER have been considered [6,15,17] for their ability to reduce FIV infectivity [18]. In this context, the 20-mer gp36 L767-M786, the octapeptide gp36 W770-I777 (C8), and the hexapeptide D772-I777 (C6a) were previously identified as molecules exerting antiviral activity by preventing
the penetration of FIV into the host cells. These peptides, endowed with a strong membrane binding property, were studied using several physico-chemical techniques; important information regarding their conformational properties was acquired using NMR-based conformational analysis [15,19,20].

Extending our previous work, using DNA recombinant techniques, we designed and produced a small protein corresponding to the gp36 fragment L\textsuperscript{737-786}. This polypeptide, including the 20- and 8-mer fragments previously analysed by us, encompasses the entire gp36 MPER and part of its adjacent CHR region. In the present work, we report the NMR analysis of \textsuperscript{15}N/\textsuperscript{13}C-enriched \textsuperscript{737-786} gp36 CHR–MPER in a dodecyl phosphocholine/sodium dodecyl sulfate (DPC/SDS) micelle solution. Then, we investigated the positioning of \textsuperscript{737-786} gp36 CHR–MPER on the micelle surface and the 1,2-dioleoyl-sn-glycero-3-phosphocholine/1,2-dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (DOPC/DOPG) phospholipid bilayer using spin label-enhanced NMR experiments and ESR spectroscopy. On a larger scale, the effect of \textsuperscript{737-786} gp36 CHR–MPER on the size and shape of DOPC/DOPG multilamellar vesicles was studied by confocal microscopy imaging.

Despite the biological importance of MPER regions for the entry of lentiviruses into the respective host cells, several issues regarding their structure and mode of action are still obscure. Moreover, while MPER, together with several other fragments of gp41, have been studied by NMR and X-ray crystallography under a wide range of conditions [21–24], the structure of gp36 is almost unexplored. Only recently, data based on mass spectrometry confirmed the tendency of gp36 to form a six-helical bundle, which is analogous to gp41 [15,19,20,25–34].

In this context, our data provide the first high-resolution structure of gp36 MPER linked to CHR. They represent a useful contribution for clarifying the MPER molecular mechanism and its role in the interactions with the host cell membranes, with adjacent domains and the other gp36 monomers for the formation of the trimer.

The structure of \textsuperscript{737-786} gp36 CHR–MPER is discussed and compared with the structure of the corresponding region of gp41 and gp36 peptides that we previously studied. The specific disposition of Trp sidechains represents a key structural element, enabling a common molecular mechanism even in the presence of different amino acid sequences [35]. These elements inspire the design of new potential entry inhibitors that interfere with the formation of the trimer or replace MPER in the interaction with the lipid membrane.

2. Results

2.1. Circular Dichroism of \textsuperscript{737-786} gp36 CHR–MPER

Circular dichroism (CD) spectra of \textsuperscript{737-786} gp36 CHR–MPER were recorded in mixed DPC/SDS (90:10 M/M) micelles and in MLVs composed of DOPC/DOPG 90:10 M/M vesicles [36–39]. Both MLVs and micelle solutions are often used as biomimetic membrane models to study the structural features of membranotropic molecules. Micelles are made of surfactants, including zwitterionic DPC and negatively charged SDS, at much higher concentrations than their critical micelle concentration (c.m.c.). These surfactants form spherical aggregates, in which the polar headgroups are located on the surface, and the hydrophobic tails point to the centre. Micelle solutions are ideal systems for solution CD and NMR spectroscopy experiments, as they tumble rather quickly, resulting in high-resolution spectral lines [34,40,41].

Figure 2 shows the CD spectra of \textsuperscript{737-786} gp36 CHR–MPER collected in DPC/SDS 90:10 M/M and DOPC/DOPG 90:10 M/M MLVs. A qualitative analysis of CD curves indicates that \textsuperscript{737-786} gp36 CHR–MPER has similar conformational propensities in the two solvent systems. Quantitative estimation of CD data using the DICHROWEB website with CONTIN and SELCON3 analytical algorithms [42] shows that \textsuperscript{737-786} gp36 CHR–MPER in the DPC/SDS membrane mimicking system assumes 58% α-helix, 9% β-sheet and 33% random coil conformations, while in DOPC/DOPG, it assumes 69% α-helix, 4% β-sheet and 27% random coil conformations.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 4 of 20

shows that 737-786gp36 CHR–MPER in the DPC/SDS membrane mimicking system assumes 58% α-helix, 9% β-sheet and 33% random coil conformations, while in DOPC/DOPG, it assumes 69% α-helix, 4% β-sheet and 27% random coil conformations.

Figure 2. Processed far-UV CD spectra of 737-786gp36 CHR–MPER in multilamellar vesicles (MLVs) composed of dodecyl phosphocholine/sodium dodecyl sulfate (DPC/SDS) 90:10 M/M (dashed line) or 1,2-dioleoyl-sn-glycero-3-phosphocholine/1,2-dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (DOPC/DOPG) 90:10 M/M (dotted line). CD spectra were acquired using a JASCO-810 spectropolarimeter at room temperature with a cell path length of 1 mm. The measurement range spans from 200 to 260 nm.

2.2. NMR Structure Determination

We expressed and purified a recombinant protein that includes the CHR and MPER segments of gp36. The structure and backbone dynamics of 737-786gp36 CHR–MPER were studied using solution NMR spectroscopy in mixed DPC/SDS (90:10 M/M) micelles [34,40,43]. Two-dimensional (2D) 1H-13C-HSQC/1H-15N-HSQC spectra of (15N-13C)-labelled 737-786gp36 CHR–MPER show all the characteristics of a stably folded protein, with 48 well-dispersed amide chemical shifts and uniform resonance line widths (Supplementary Materials, Figure S1). Backbone chemical shift assignment was carried out by iteratively analysing 2D 1H-13C-HSQC/1H-15N-HSQC spectra and 3D HNCO, and HN(CA)CO spectra (SPARKY software) [44]. A similar procedure was used for chemical shift assignments of protein side chains by inspecting HBHA(CO)HN, CBCA(CO)HN, and HNCACB heteronuclear spectra [45–47]. 1H, 13C, and 15N chemical shifts are reported in the Supplementary Materials (Table S1).

The secondary chemical shifts of 13Cα, which refer to the difference between the observed chemical shifts and the corresponding residue-specific random coil values, are sensitive indicators of the local secondary structure [48,49]. Large positive values of 13Cα secondary chemical shifts suggesting α-helix structure are observed for the residues T739-E748 and L751-E754, which correspond to the CHR region. Conversely, the 13Cα chemical shift values of Q755-W770 and L777-M786 are typical of random coil structures, indicating that these regions are dynamically disordered in solution (Figure 3).
suggesting α-helix structure are observed for the residues T739-E748 and L751-E754, which correspond to the CHR region. Conversely, the $^{13}$C$\alpha$ chemical shift values of Q755-W770 and I777-M786 are typical of random coil structures, indicating that these regions are dynamically disordered in solution (Figure 3).

The structure of 737-786gp36 CHR–MPER in the micelle-bound state was derived by simulated annealing calculations, based on 443 sequential and short-range NOE distance restraints and 72 backbone dihedral angle restraints (Supplementary Materials, Table S2). The prediction of backbone dihedral angles was provided by the TALOS+ program [50]. Regular sequential and medium-range NOE effects, N,N(i, i+2), $\alpha$,N(i, i+2), $\alpha$,N(i, i+3) and $\alpha$,β(i, i+3) (Figure 3), were observed in three-dimensional nuclear Overhauser enhancement (3D-NOESY) spectra collected in DPC/SDS micelle solutions. These were translated into interprotonic distances using the CALIBA routine of CYANA 2.1 software [51] and were used as restraints in NMR structure calculations (Supplementary Materials, Table S2). Statistics for the final NMR ensemble are summarized in Table 1 [52].

**Table 1.** Statistics for the structural calculation of the NMR Ensemble of 737-786gp36 CHR–MPER.

| Number of NOESY Peaks | Total 457 |
|----------------------|----------|
| Number of Experimental Restraints after CYANA | |
| Total NOEs | 445 |
| Intra-residual | 294 |
| Sequential | 122 |
| Medium-range | 20 |
| Long-range | 9 |
| Dihedral angles | 73 |

| RMSD | bb/heavy Å 1.38/1.98 |
|------|----------------------|
| Ramachandran Analysis | |
| Favourable regions | 78.40% |
| Additionally allowed regions | 19.30% |
| Generously allowed regions | 2.30% |
| Disallowed regions | 0% |

Figure 4 shows the NMR structure bundle of 737-786gp36 CHR–MPER as derived from the CYANA and TALOS+ calculations [50]. The structures show a good level of structural definition by the
residues E748-G760 and Q765-Y774, resulting in a 1.10 Å root-mean-square deviation (RMSD) value for the backbone. Quantitative estimation of backbone dihedral angles, according to PROMOTIF [53], using Kabash and Sanders parameters, points to the presence of the following secondary structure segments: (i) α-helix for T739-Y747 residues, (ii) 3_10 helix for E748-G760 and Q765-L784 residues, (iii) type II β-turn for K761-I764 residues. This last segment characterized by a higher flexibility defines a kink segment regulating the reciprocal position of the T739-Y747 α-helix and E748-G760 3_10 helix, with an average angle of 43.9° (Figure 4A). The structure was deposited in the Protein Data Bank (PDB ID: 6FTK). The flexibility of the interhelical linker suggests that the relative orientation and position on the lipid surface are subject to large dynamic disorder, and the structure shown in Figure 4A represents an average view.

The dynamics of the 737-786 gp36 CHR–MPER backbone were determined by measuring relaxation parameters by solution NMR. Figure 5 reports the values of the T1, T2, and steady-state NOE values of the amide resonances plotted against the residue numbers. The NOE, T1, and T2 values are correlated with the mobility of each amide in the protein backbone, and this affects the rate at which an excited nucleus can explore the fluctuating fields around it to exchange energy and relax [54]. The relaxation data point to three different motional regimes: a rigid N-terminal portion (residues 738-757) with NOE values and particularly low NOE values. Figure 5 + reveals that the N- and C-terminal helices have very similar T1/T2 ratios; this may be consistent with the two helices oriented at a 43.9° angle, resulting from the CYANA-simulated annealing. The experimental data are enforced by the random coil index (RCI) obtained by plotting the S2 values predicted by TALOS+. 

**Figure 4.** NMR structure of (15N-13C)-labelled 737-786 gp36 CHR–MPER in DPC/SDS 90:10 M/M. (A) Ribbon of the representative structure of the calculated ensemble; (B) N-terminal region, consisting of the N-helix residues Q738-N756; (C) C-terminal region containing the C8 peptide; (D) β-turn region containing residues N757-Q766.
motion (Trp770 and Val774). These are characterized by the longest T2 values and particularly low NOE values. Figure 5 reveals that the N- and C-terminal helices have very similar T1/T2 ratios; this may be consistent with the two helices oriented at a 43.9° angle, resulting from the CYANA-simulated annealing. The experimental data are enforced by the random coil index (RCI) obtained by plotting the S2 values predicted by TALOS+.

Figure 5. 15N backbone relaxation measurements for 737-786 gp36 CHR–MPER in DPC/SDS micelles. 1H-15N heteronuclear NOE, T1, and T2 experiments were performed on a 600 MHz spectrometer (see Materials and Methods for experimental details). Plot of the T1/T2 ratios obtained from T1 and T2 data. Predicted random coil index (RCI) histogram plotted from S2 values obtained using the TALOS+ routine (see Table S1 for data in detail). The α-helices are reported as grey cylinders in the one-letter sequence of 737-786 gp36 CHR–MPER at the top, while the 310 helix is reported as a white tube.

2.3. NMR Spin-Label Analysis

NMR analysis in DPC/SDS 90:10 M/M micelle solution was the starting point to investigate the positioning of 737-786 gp36 CHR–MPER on the micelle aggregates. For this purpose, we recorded NMR spectra of 737-786 gp36 CHR–MPER in the presence of 5-doxylstearic acid (5-DSA), which was included in the micelles as paramagnetic probes. 5-DSA contains a doxyl group, a cyclic nitroxide with an unpaired electron, bound to the aliphatic chain carbon at position five. Paramagnetic probes induce a broadening of the NMR signals and a decrease in resonance intensities of the neighbouring protons; thus, if the protein is close to the surface or penetrates the inner core of 5-DSA spin-labelled micelles, a decrease in intensities is observed [41]. Specifically, signals of protein residues that are closer to the NO moiety are more affected by unpaired electrons.

The 2D 1H-15N-HSQC spectra of (15N-13C)-labelled 737-786 gp36 CHR–MPER were recorded in DPC/SDS 90:10 M/M micelle solutions in the absence and presence of 5-DSA. 1H-15N-HSQC spectra of 15N labelled 737-786 gp36 CHR–MPER show changes in the intensities of HN backbone signals. Figure 6 reports the variations in the backbone NH intensities (Δ%) when 5-DSA is added to the micelles. NH signals of N756, Q759, L767, W776, G778, I780, and εNH of W770 and W776 were subject to a decrease in intensity from 50% to almost 100%, indicating close contact with the lipid environment. The other residues, not being affected by any chemical shift variation, were assumed to be far from the membrane surface (Figure 6).
of 15N labelled 737-786 gp36 CHR–MPER show changes in the intensities of HN backbone signals. Figure 6 reports the variations in the backbone NH intensities (Δ%) when 5-DSA is added to the micelles.

NH signals of N 756, Q759, L767, W776, G778, I780, and εNH of W770 and W776 were subject to a decrease in intensity from 50% to almost 100%, indicating close contact with the lipid environment. The other residues, not being affected by any chemical shift variation, were assumed to be far from the membrane surface (Figure 6).

Figure 6. Percentage variation (Δ%) of intensities of HN backbone peaks of (15N-13C)-labelled 737-786 gp36 CHR–MPER in the DPC/SDS 90:10 M/M micelle solution obtained by integrating 2D 1H-15N-HSQC spectra recorded at 300 K in the absence and presence of 5-doxylstearic acid (5-DSA) at a concentration of one spin label per micelle. The residues that show a decrease in intensity from 50 to 100% are highlighted in blue. At the top right is a model of the interaction between 737-786 gp36 CHR–MPER and micelles.

2.4. ESR Spin-Label Analysis

To determine whether the interaction with 737-786 gp36 CHR–MPER influenced the microstructure of DPC/SDS 90:10 micelles, we performed ESR measurements on micelle solutions in the presence and absence of the peptide. Since its ESR spectrum is strongly affected by the microenvironment in which it is embedded, 5-DSA is a spin-probe suitable for this kind of study. Spectroscopic parameters obtained from the 5-DSA spectra are shown in Table 2. Two parameters can be obtained from the spectra analysis: the nitrogen isotropic hyperfine coupling constant, $A_N$, which increases with the polarity of the medium in which the nitroxide is embedded, and the nitroxide correlation time, $\tau_C$, which depends on the label rotational mobility that is determined by the microenvironment viscosity and/or by specific interactions. Inspection of Table 1 shows that $\tau_C$ increases in the presence of 737-786 gp36 CHR–MPER, indicating a reduction in the label mobility. This evidence should be ascribed to at least a partial insertion of the peptide, or of a segment of it, in the micelles, since the local structuring of the alkyl chain tends to be more ordered in the proximity of a guest molecule [55]. The local polarity, as monitored by $A_N$, does not change, indicating that the peptide interaction does not favour water penetration in the micelle.
Table 2. Nitrogen coupling constant, $A_N$, spin-label correlation time, $\tau_C$, for 5-DSA in micelles and outer hyperfine splitting, $2A_{\text{max}}$, for 5-PCSL measured by ESR experiments in the absence and presence of $737$-$786$ gp36 CHR–MPER.

| System               | $A_N$/G | $\tau_C \times 10^{10}$/s | $2A_{\text{max}}$/G |
|----------------------|---------|---------------------------|----------------------|
| 5-DSA                |         |                           |                      |
| DPC/SDS 90:10        | 14.5 ± 0.1 | 27 ± 2                  | -                    |
| DPC/SDS 90:10 + $737$-$786$ gp36 CHR–MPER | 14.6 ± 0.1 | 42 ± 3                  | -                    |
| 5-PCSL               |         |                           |                      |
| DOPC/DOPG 90:10      | -       | -                         | 51.2 ± 0.1           |
| DOPC/DOPG 90:10 + $737$-$786$ gp36 CHR–MPER | - | - | 52.4 ± 0.2 |

The interaction of $737$-$786$ gp36 CHR–MPER with the mixed DOPC/DOPG 90:10 M/M bilayer was also investigated through ESR experiments to analyse the spectra of the 5-phosphatidylcholine spin-labelled lipid (5-PCSL) included in the membrane. In this case, to quantitatively detect the perturbations of the lipid packing due to the peptide interaction, the outer hyperfine splitting, $2A_{\text{max}}$, which is an index of restriction of the local mobility of the acyl chains, was derived from the spectra analysis [25,31]. The $2A_{\text{max}}$ value of 5-PCSL increased by 1.2 G in the presence of $737$-$786$ gp36 CHR–MPER, revealing the stiffening of the bilayer due to the peptide interaction. A comparison between the ESR results obtained for the micelles and the liposomes shows that, in both kinds of aggregates, the interaction with the peptide significantly perturbs the surfactant (or lipid) organization, inducing a lower fluidity of the self-assembled molecules. As the reporter nitroxide group was being positioned along the tail in close proximity to the hydrophilic head group, the results indicate that the peptide penetrates at least in the region of the aggregate (micelle or bilayer) that is just underneath its interface with the aqueous medium, suggesting the involvement of the peptide in the aggregate microstructure.

2.5. Confocal Microscopy Imaging

Confocal microscopy imaging of $737$-$786$ gp36 CHR–MPER was carried out in labelled MLVs of DOPC/DOPG 90:10 M/M. DOPC included 2.25 mM of 1-palmitoyl-2-{6-[7-nitro-2,1,3-benzoxadiazol-4-yl]amino}hexanoyl-sn-glycero-3-phosphocholine (NBD-PC) for fluorescence visualization. Labelled MLVs were imaged in the absence and presence of $737$-$786$ gp36 CHR–MPER (Figure 7). Experiments were repeated at different $737$-$786$ gp36 CHR–MPER concentrations and at different times after deposition. Specifically, the concentrations of 0.5, 0.25, and 0.05 mM $737$-$786$ gp36 CHR–MPER were used, and images were acquired 5 min and 60 min after deposition. The best experimental conditions were obtained at 0.05 M $737$-$786$ gp36 CHR–MPER concentration. Figure 7A reports confocal microscopy images of MLVs composed of DOPC/DOPG 90:10 M/M in the absence of $737$-$786$ gp36 CHR–MPER. In these conditions, labelled MLVs assume a spherical shape, with a diameter ranging from ~1 to 10 μm.

Figure 7B show fluorescently labelled MLVs composed of DOPC/DOPG 90:10 M/M and NBD-PC in the presence of 0.05 mM $737$-$786$ gp36 CHR–MPER. In these conditions, the diameter of vesicles increased due to highly dynamic budding and fusion events. Large spherical liposomes characterized by 5–30 μm diameters often appear because of the impaired budding of smaller vesicles. Remarkably, labelled MLVs were interconnected through the formation of straight-chain tubular structures (Figure 7B–D) that often extend throughout the entire field of view and beyond and are typically capped at both ends with large liposomal structures. These “tubulation” events occur in different z-planes, forming a crowded three-dimensional network of tubules and liposomes.
As evident from the NMR structure bundle and according to the relaxation data (Figure 5), the possibly design antiviral entry inhibitors. Moreover, these data are of great interest in veterinary of the gp36 MPER structure with the structure of the corresponding region of gp41 and Ebola envelope α CHR evident that the structure of each segment fits with the relative biological function: (i) the regular structural features of 737-786 

glycoprotein is of great interest as it provides an experimental model to investigate HIV entry and high-resolution structure of such an extended domain of gp36. The study of the FIV envelope in lentivirus glycoproteins. As structural data on gp36 are almost missing, we provide the first structure remain unclear, perhaps due to its conformational plasticity and chameleon-like structure.

We previously studied several peptides belonging to the MPER of FIV gp36. The 20-mer gp36 L767 M786, the octapeptide gp36 W770 L777 (C8), and the hexapeptide D772-I777(C6a) exhibited antiviral activity and were analysed using several physicochemical techniques, including NMR spectroscopy. Extending this work, we report the NMR structure determination of a small protein, L737-M786, which includes the entire gp36 MPER and part of its adjacent CHR region.

Our study provides additional data to interpret the structure-activity relationship of MPER in lentivirus glycoproteins. As structural data on gp36 are almost missing, we provide the first high-resolution structure of such an extended domain of gp36. The study of the FIV envelope glycoprotein is of great interest as it provides an experimental model to investigate HIV entry and possibly design antiviral entry inhibitors. Moreover, these data are of great interest in veterinary medicine, given the wide spread of FIV infection.

As shown in Figure 4, the structure of the 737-786 gp36 CHR–MPER in DPC/SDS 90:10 micelles consists of a helix–turn–helix motif, where CHR and MPER are an α-helix and a 3_10 helix, respectively. As evident from the NMR structure bundle and according to the relaxation data (Figure 5), the α-helix corresponding to part of the CHR (residues 738-757) is rigid and regular compared to the helix corresponding to MPER; the MPER helix is moderately flexible and includes residues with fast internal motion. A flexible loop (residues 758-763) connects the two helices, as demonstrated by low heteronuclear NOE values and a relatively limited number of experimental NMR restraints. However, consistent with the T_1/T_2 values, the two helices are oriented at an average angle of ~43°. By analysing the structural features of 737-786 gp36 CHR–MPER in light of a structure–function relationship, it is evident that the structure of each segment fits with the relative biological function: (i) the regular CHR α-helix has a close interaction with the NHR segment (see Figure 1), (ii) the moderately flexible MPER has a less specific interaction with the lipid membrane, and (iii) the flexible CHR–MPER loop facilitates the repositioning of CHR and MPER to interact with their respective targets. The comparison of the gp36 MPER structure with the structure of the corresponding region of gp41 and Ebola envelope
glycoprotein indicates that moderate flexibility is typical of all the MPER domains that have been solved thus far.

Analysis of the positioning of \( ^{737-786} \text{gp36 CHR–MPER} \) on lipid membranes by using spin label-enhanced experiments indicates that the C-terminus of gp36 MPER, including \( W^{773} \) and \( W^{776} \), together with the residues flanking the loop, \( G^{760} \), and \( Q^{765} \), lies in the membrane interface, which is well embedded in the lipid headgroup region. ESR experiments, in particular, confirm the insertion of the peptide in the micelles, as well as in the region of the DOPC/DOPG bilayer just underneath its interface with the aqueous medium (Table 1). As demonstrated by confocal microscopy imaging, this interaction destabilizes the bilayer aggregate, determining the change in size and shape of the vesicles. Figure 7 shows that \( ^{737-786} \text{gp36 CHR–MPER} \) induces the highly dynamic budding and fusion events of the membrane to form a network of MLVs interconnected by straight membrane tubes.

\( W^{773} \) and \( W^{776} \) are confirmed to be important residues for effective interaction with the membrane surface. As mentioned, we previously studied the fragments of \( ^{737-786} \text{CHR–MPER} \) C8, C6a, and C6b in the context of the identification of new antiviral compounds [35]. C8 and C6a correspond to \( W^{770} - I^{777} \) and \( D^{772} - I^{777} \) of gp36 MPER, respectively [15,19,20,27–33]. Both of them, including \( W^{773} \) and \( W^{776} \), exhibited antiviral activity that prevents the entry of FIV into the host cell; correspondingly, both peptides exhibited strong membrane-binding properties. On the other hand, C6b, corresponding to the \( W^{770} - C^{775} \) fragment, although very similar to C8 and C6a, was almost inactive as an antiviral peptide and devoid of any relevant ability of binding to the phospholipid bilayer.

By analysing the molecular surfaces calculated as propensities of the different portions of the molecules to interact, according to the specific surface properties, we speculate that the effective interaction with a lipid membrane significantly depends on the profile of the molecular surface. While \( ^{737-786} \text{gp36 CHR–MPER} \), C8, C6a, showing a strong membrane binding property, exhibit an extended hydrophobic molecular surface derived from the exposure of the \( W^{773} \) and \( W^{776} \) indolyl rings, C6b shows a modest membrane binding property due to the limited implication of the \( W^{770} \), and \( W^{773} \) indolyl rings in interacting with the external medium. A similar analysis, applied to the MPER structure of gp41, reveals the great potential of this region to bind the lipid membrane surface due to the presence of two additional Trp residues (Figure 8).

Molecular dynamics performed on the C8 peptide using enhanced sampling approaches demonstrated that the binding of C8 with membrane phospholipids involves H-bonds and electron transfer with Trp residues and ionic interactions with the negative charges of D\(^{772}\). Using these data and those from the NMR analyses of C6a and C6b in micelle solution, we previously defined a pharmacophore model [35], including the indole rings of two Trp residues and the D\(^{772}\) carboxylate (Figure 9). The MPER structure of gp36 and gp41, as derived from NMR data, fit with this model: (i) by considering the distances among D\(^{772}\), \( W^{770} \), and \( W^{773} \) on the one hand or among D\(^{772}\), \( W^{773} \) and \( W^{776} \) on the other hand in \( ^{737-786} \text{gp36 CHR–MPER} \) (Figure 9) and (ii) by considering the distances among N\(^{674}\), W\(^{672}\), and W\(^{678}\) on the one hand or N\(^{674}\), W\(^{670}\) and W\(^{680}\) on the other hand in gp41 MPER. Remarkably, gp41, due to the presence of two additional Trp residues, fits this model in more than one manner.
Figure 8. Surface analyses of the Trp and Asp residues contained in (A) C8, C6a, and C6b peptides and (B) gp41 and gp36 MPER domains. The patches are coloured green for hydrophobic surfaces, red for negatively charged surfaces, and blue for positively charged surfaces.

Molecular dynamics performed on the C8 peptide using enhanced sampling approaches demonstrated that the binding of C8 with membrane phospholipids involves H-bonds and electron transfer with Trp residues and ionic interactions with the negative charges of D772. Using these data and those from the NMR analyses of C6a and C6b in micelle solution, we previously defined a pharmacophore model [35], including the indole rings of two Trp residues and the D772 carboxylate (Figure 9). The MPER structure of gp36 and gp41, as derived from NMR data, fit with this model: i) by considering the distances among D772, W770, and W773 on the one hand or among D772, W773 and W776 on the other hand in 737-786gp36 CHR–MPER (Figure 9) and ii) by considering the distances among N674, W672, and W678 on the one hand or N674, W670 and W680 on the other hand in gp41 MPER.

Remarkably, gp41, due to the presence of two additional Trp residues, fits this model in more than one manner.

Taken together, these data show that MPER domains in different envelope glycoproteins and, in particular, the Trp-rich sequence within MPER may be considered polyfunctional molecular tools with amplified membrane-binding properties. These are designed by nature to manipulate phospholipid aggregates, regulating cell membrane fusion or cell membrane tubulation in important events related to cell trafficking and cell communication.
Figure 9. The structures of gp36 MPER (B) and gp41 MPER (C) fit the pharmacophore model of C8 and C6a previously identified [35] (A). Dashed lines show the distances in Å between the key functional moieties.

4. Materials and Methods

4.1. Protein Expression and Purification

The pET-31b(+) vector (Novagen, Cat. No. 69952-3) is designed for cloning and high-level expression of peptide sequences and is fused with the 125 aa ketosteroid isomerase protein (KSI) [62]. The construct was designed with three mutated amino acids, N737L, M751L, and G786M, to selectively remove the KSI-tag and His-tag using CNBr. The expression vector pET-31b(+) was transformed into BL21(DE3)pLysS cells and used for expression in E. coli. For the expression of uniformly, 15N and 13C-isotope-labelled 737-786 gp36 CHR–MPER protein in E. coli, M9 minimal media [63] (6 g Na2HPO4, 3 g of KH2PO4, 0.5 g of NaCl dissolved in 900 mL of distilled water) containing 50 µg/mL ampicillin and 1 g of 15N ammonium sulfate was prepared and autoclaved. Then, 20% 13C glucose solution, prepared with 2 g of 13C glucose, 10 mL of vitamin cocktail and trace metal solutions (1 mL of 1 M stock solutions of thiamine, MgSO4, and CaCl2, sterilized by filtration) was added, and the final volume was adjusted to 1 L. The overnight culture (20 mL of LB (Luria Bertani) medium was used to inoculate 1 L of M9 medium. When bacterial clones reached an OD 600 of 0.5 at 37°C, 1 mM IPTG was added. After 18 h, cells were pelleted by centrifugation and resuspended in lysis buffer (0.5 M NaCl and 20 mM Tris-HCl), sonicated, and recentrifuged. The obtained pellet was suspended in binding buffer (10 mM guanidine, 0.5 M NaCl, 20 mM Tris-HCl, and 15 mM imidazole) and stirred for one night at 4°C. Then, the solution was purified with a His-Trap™ HP column at 1 mL/min using an AKTA purifier system; the protein was eluted from the column with elution buffer (10 mM guanidine, 0.5 M NaCl, 20 mM Tris-HCl and 50 mM imidazole). The eluted fraction was dialyzed and lyophilized. To remove the
KSI-tag [62,64], the lyophilized protein was dissolved in a minimum quantity of 70% (v/v) formic acid and treated with 0.5 M cyanogen bromide; the reaction was stirred for 3 h in the dark. After 3 h, the solution was dialyzed and lyophilized. Finally, the protein was purified by HPLC (Supplementary Materials, Figure S2).

4.2. Mass Spectrometry Analysis

One microgram of 737-786 gp36 CHR–MPER was digested by using 13 ng/µL of sequencing grade modified trypsin solution (Promega, USA) in 10 mM AMBIC (NH₄HCO₃) at 37 °C for 18 h. The reaction was stopped by adding 1 µL of 1% trifluoroacetic acid (TFA). The peptide mixture resulting from proteolytic digestion was mixed with a 1 µL matrix and spotted on a 100-well stainless-steel sample plate. The matrix was 5 mg/mL α-cyano-4-hydroxycinnamic acid dissolved in 50% acetonitrile solution (Sigma-Aldrich) with 0.1% TFA (Sigma-Aldrich). The analyses were performed on a MALDI-TOF mass spectrometer (MALDI micro MX, Waters) in the positive reflector mode. After acquisition, the spectra were externally calibrated with the calibration mixture, MassPREP™ peptide standard mixture (Waters). The analysis of the monoisotopic peptide mass lists fully covered the 737-786 gp36 CHR–MPER sequence.

4.3. Circular Dichroism Spectroscopy

CD experiments were performed at 25 °C on an J-810 Jasco spectropolarimeter as an average of four scans with 10 nm/min scan speed, 4 s response time and 2 nm bandwidth, using a quartz cuvette with a path length of 1 mm, a measurement range from 190 to 260 nm (far UV), and a temperature of 25 °C. Throughout the measurements, the trace of the high-tension voltage was verified to be less than 700 V, which ensures the reliability of the obtained data.

Far UV CD spectra of mixed micelles (DPC/SDS 90:10 M/M (27 mM/3 mM)) in aqueous solution (pH 7.4, 10 mM phosphate buffer containing H₂O₂), MLVs of DOPC/DOPG (90:10 M/M) and 500 µM 737-786 gp36 CHR–MPER were added to mimic membrane systems for the conformational analysis [41]. The processed curve of 737-786 gp36 CHR–MPER in mixed micelles was obtained by using the Spectra Analysis tool in the Jasco software. The CD curve of 737-786 gp36 CHR–MPER in mixed micelles was corrected for the solvent contribution by subtracting the CD reference spectrum, and then the final CD spectrum was obtained after baseline correction and binomial smoothing. This resulting spectrum was used for the estimation of the secondary structure content using the algorithms CONTIN and SELCON3 from the DICHROWEB website [42].

4.4. NMR Spectroscopy

4.4.1. Spectra Acquisition

Three-dimensional NMR experiments of 737-786 gp36 CHR–MPER in DPC/SDS mixed micelles were acquired on a Bruker 900 MHz spectrometer. Then, 0.5 mg of isotope-labelled 737-786 gp36 CHR–MPER was dissolved into a DPC/SDS micelle solution (DPC concentration was 27 mM (27 times higher than the critical micellar concentration (c.m.c.) of DPC), and the SDS concentration was 80 mM (10 times higher than the c.m.c. of SDS)) [65]. The DPC/SDS molar ratio was 90:10 (27 mM/3 mM) to produce a partial (2%-3%) negative charge, which is present in the typical membrane of eukaryotic cells [43]. The final pH was 7.4. For NMR experiments, d²⁵SDS and d³⁸DPC were used from Avanti® Polar Lipids, Inc. NMR experiments were recorded at 300 K. Standard backbone, and side-chain assignment experiments (CBCA(CO)NH, HNCACB, HNCO, HN(CA)CO, HBHA(CO)NH, and HCCH-TOCSY) [46] were acquired with 1024 increments of 512 time points and 16 scans each on a 600 MHz Bruker Avance III spectrometer equipped with a TXI probe, running with TopSpin 2.1. On this spectrometer, T₁, T₂, and relaxation experiments were also recorded. T₁, relaxation curves were fit from signal intensities in HSQC experiments recorded as pseudo-3D experiments using relaxation delays of 10, 20, 40, 80, 160, 400, 1000, 2000, 4000, 6000 and 7000 ms. T₂ times were obtained from fitting HSQC signal intensities
after recording pseudo-3D experiments with 31.7 (2 times), 63.4, 95.1, 126.8 (2 times), 158.6, 190.3, 222.0, 253.7 and 285.4 ms. The 2D NOESY, 3D $^{13}$C-NOESY-HSQC, and $^{15}$N-NOESY-HSQC experiments were recorded with 100 ms mixing times using a 900 MHz Bruker Avance III NMR spectrometer equipped with a TCI cryoprobe and running with TopSpin 3.0.

4.4.2. Assignment of NMR Resonances and TALOS+ Analysis

Qualitative and quantitative analyses of 3D NMR spectra were achieved using SPARKY software [44]. Intramolecular distance restraints derived from nuclear Overhauser enhancements (NOEs) were obtained from the $^{15}$N-NOESY spectrum recorded on a 900 MHz spectrometer. The assigned chemical shift values of backbone $^{15}$N, $^{13}$C$_\alpha$, and $^{13}$C' were used as input for the TALOS+ program [50] to predict backbone dihedral angles. Forty-two out of 44 residues with assignments and dihedral angles of 42 residues were considered ‘GOOD’ by TALOS+.

4.4.3. Structure Calculation

Peak volumes were translated into upper distance bounds with the CALIBA routine from the CYANA 2.1 software package [51]. After discarding redundant and duplicated constraints, the final list of constraints was used to generate an ensemble of 50 structures by the standard CYANA protocol of simulated annealing in torsion angle space (using 6000 steps). The entries that present the lowest target function value (0.83–1.19) and small residual violations (maximum violation = 0.38 Å) were analysed using the PyMOL program [66].

4.4.4. NMR Spin-Label Experiments

2D $^1$H-$^{15}$N-HSQC experiments of 0.5 mg of $^{737-786}$gp36 CHR–MPER in DPC/SDS mixed micelles were acquired in the absence and in the presence of 5-doxylstearic acid (5-DSA). 5-DSA purchased from Merck was withdrawn from a 10 mM methanol-d$_4$ stock solution. All experiments were acquired with 512 increments of 256 time points and 32 scans on a 600 MHz Bruker Avance III spectrometer equipped with a TXI probe, running with TopSpin 2.1.

4.5. ESR Spectroscopy

The effect of $^{737-786}$gp36 CHR–MPER on the surfactant arrangement in DPC/SDS 90:10 micellar aggregates was investigated by analysing the ESR spectrum of the spin label 5-doxylstearic acid (5-DSA; Sigma). Moreover, the effect of $^{737-786}$gp36 CHR–MPER on lipid self-organization in DOPC/DOPG 90:10 liposomes was investigated by analysing the ESR spectrum of the spin label 1-palmitoyl-2-stearoyl-(5-doxyl)-sn-glycero-3-phosphocholines (5-PCSL; Avanti Polar Lipids). In both micellar and liposomal systems, the peptide/surfactant (peptide/lipid) molar ratio was set at 1:50, and the spin label was inserted into the self-assembled aggregates at a 1:100 label/surfactant (label/lipid) molar ratio, with a fixed total surfactant (or lipid) concentration of 30 mM.

The samples, prepared according to well-assessed procedures reported in previous works [67,68], were deoxygenated and sealed in 1.00 mm i.d. quartz capillaries. ESR spectra were obtained using a Bruker ELEXYS e500 X-band spectrometer using instrumental settings reported elsewhere [55,69]. All measurements were performed at 25 ± 1 °C.

ESR spectra of 5-DSA in micellar systems showed narrow lines indicative of an isotropic fast motion. Consequently, the spectral analysis was carried out according to the classical theory of motional narrowing for ESR lines using a line-shape analysis protocol reported in the literature. On the other hand, the ESR spectra of 5-PCSL in liposomes showed a slightly, but evidently anisotropic, line shape. In this case, semiquantitative analysis of the spectra was carried out by determining the outer hyperfine splitting, $2A_{\text{max}}$, which is the difference between the low-field maximum and the high-field minimum [25].
4.6. Confocal Microscope Imaging

The multilamellar lipid vesicles (MLVs) of DOPC/DOPG (90:10, M/M) with 2.25 mM NBD-PC were prepared by mixing appropriate amounts of lipids dissolved in a dichloromethane/methanol mixture (25 mM lipid concentration) in a round-bottom test tube. The solutions were desiccated, dried overnight, and hydrated in 10 mM phosphate buffer at pH 7.4. The total weight of the lipid for each sample was 1.0 mg. During their formation, labelled MLVs were prepared by adding 737-786 gp36 CHR–MPER at concentrations of 0.50, 0.25 and 0.05 mM. The last concentration, corresponding to the lipid-to-peptide ratio of 50:0.1 M/M, was used for the imaging shown in Figure 7.

A total of 10 µL of each solution, in the presence or absence of 737-786 gp36 CHR–MPER, was taken and spotted onto a cover slip. Images were acquired as previously described [70,71] at 5 and 60 min after deposition on a laser scanning confocal microscope (LSM 510; Carl Zeiss Micro-Imaging) equipped with a plan Apo 63X, NA 1.4 oil immersion objective lens. For each field, both fluorescent and transmitted light images were acquired on separate photomultipliers and were analysed using Zeiss LSM 510 4.0 SP2 software. In samples in which different z-planes were distinguishable, a z-stack acquisition mode was performed to focus a single z-plane, as published previously [72].

Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/6/2037/s1.

Author Contributions: Conceptualization, A.M.D. and M.G.; methodology, M.G., M.B., A.S., M.S., I.S., G.A., A.T., O.M., D.E., H.L.J.W.; software, M.G., M.B., M.S.; investigation, M.G., M.B., A.S., M.S., I.S., G.A., D.E., G.D.; data curation, M.G., M.B., I.S., G.A.; writing—original draft preparation, A.M.D., M.G., M.B.; writing—review and editing, A.G., T.R.; supervision, P.R., A.M.D.; project administration, A.M.D.; and funding acquisition, A.M.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by EC FP7/2007-2013 grant number 261863.

Acknowledgments: Financial support in the form of Access to the Bio-NMR Research Infrastructure co-funded under the 7th Framework Programme of the EC (FP7/2007-2013, grant agreement 261863) for conducting the research at the SON-NMR-Large Scale Facility in Utrecht (The Netherlands) is gratefully acknowledged. Financial support by the European Union (Bio-NMR, Project 261863) for access to the SON-NMR-Large Scale Facility in Utrecht (The Netherlands) is gratefully acknowledged.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Pedersen, N.C.; Ho, E.W.; Brown, M.L.; Yamamoto, J.K. Isolation of a t-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987, 235, 790–793. [CrossRef] [PubMed]
2. Elder, J.H.; Phillips, T.R. Feline Immunodeficiency Virus As A Model For Development Of Molecular Approaches To Intervention Strategies Against Lentivirus Infections. Adv. Virus Res. 1995, 45, 225–247. [CrossRef]
3. Lee, T.; Laco, G.S.; Torbett, B.E.; Fox, H.S.; Lerner, D.L.; Elder, J.H.; Wong, C.H. Analysis of the S3 and S3 ’ subsite specificities of feline immunodeficiency virus (FIV) protease: Development of a broad-based protease inhibitor efficacious against FIV, SIV and HIV in vitro and ex vivo. Proc. Natl. Acad. Sci. USA 1998, 95, 939–944. [CrossRef] [PubMed]
4. Willett, B.J.; Flynn, J.N.; Hosie, M.J. FIV infection of the domestic cat: An animal model for AIDS. Immunol. Today 1997, 18, 182–189. [CrossRef]
5. Molinos-Albert, L.M.; Clotet, B.; Blanco, J.; Carrillo, J. Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. Front. Immunol. 2017, 8, 1154. [CrossRef]
6. Frey, S.C.S.; Hoover, E.A.; Mullins, J.I. Feline immunodeficiency virus cell entry. J. Virol. 2001, 75, 5433–5440. [CrossRef]
7. Wyatt, R.; Sodroski, J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998, 280, 1884–1888. [CrossRef]
8. Harrison, S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 2008, 15, 690–698. [CrossRef]
9. Sackett, K.; Shai, Y. The HIV-1 gp41 N-terminal heptad repeat plays an essential role in membrane fusion. Biochemistry 2002, 41, 4678–4685. [CrossRef]
10. Dwyer, J.J.; Wilson, K.L.; Davison, D.K.; Frele, S.A.; Seedorff, J.E.; Wring, S.A.; Tvermoes, N.A.; Matthews, T.J.;
    Greenberg, M.L.; Delmedico, M.K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent
    activity against enfuvirtide-resistant virus. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 12772–12777. [CrossRef]

11. Steffen, I.; Poehlmann, S. Peptide-Based Inhibitors of the HIV Envelope Protein and Other Class I Viral
    Fusion Proteins. *Curr. Pharm. Des.* **2010**, *16*, 1143–1158. [CrossRef] [PubMed]

12. Rowe, M. *The Mechanism of Small Molecule Viral Fusion Inhibitors*; The University of Alabama at Birmingham:
    Birmingham, AL, USA, 2015.

13. Liu, H.; Su, X.; Si, L.; Lu, L.; Jiang, S. The development of HIV vaccines targeting gp41 membrane-proximal
    external region (MPER): Challenges and prospects. *Protein Cell* **2018**, *9*, 596–615. [CrossRef] [PubMed]

14. Barbato, G.; Bianchi, E.; Ingallinella, P.; Hurni, W.H.; Miller, M.D.; Ciliberto, G.; Cortese, R.; Bazzo, R.;
    Shiver, J.W.; Pessi, A. Structural analysis of the epitope of the Anti-HIV antibody 2F5 sheds light into its
    mechanism of neutralization and HIV fusion. *J. Mol. Biol.* **2003**, *330*, 1101–1115. [CrossRef]

15. Giannecchini, S.; Di Fenza, A.; Di Fenza, A.; Matteucci, D.; Rovero, P.; Bendinelli, M. Antiviral activity and
    conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline
    immunodeficiency virus envelope glycoprotein. *J. Virol.* **2003**, *77*, 3724–3733. [CrossRef]

16. Mizukoshi, F.; Baba, K.; Goto, Y.; Setoguchi, A.; Fujino, Y.; Ohno, K.; Oishi, S.; Kodera, Y.; Fuji, N.; Tsujimoto, H.
    Antiviral activity of membrane fusion inhibitors that target gp40 of the feline immunodeficiency virus
    envelope protein. *Vet. Microbiol.* **2009**, *136*, 155–159. [CrossRef]

17. Pancino, G.; Camoin, L.; Sonigo, P. Structural-analysis of the principal immunodominant domain of the feline
    immunodeficiency virus membrane glycoprotein. *J. Virol.* **1995**, *69*, 2110–2118. [CrossRef]

18. Lombardi, S.; Massi, C.; Indino, E.; LaRosa, C.; Mazzetti, P.; Falcone, M.L.; Rovero, P.; Fissi, A.; Pieroni, O.;
    Bandecchi, P.; et al. Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein
    synthetic peptides. *Virology* **1996**, *220*, 274–284. [CrossRef]

19. Giannecchini, S.; Bonci, F.; Pistello, M.; Matteucci, D.; Sichi, O.; Rovero, P.; Bendinelli, M. The membrane-proximal
    tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus
    is important for cell entry. *Virology* **2004**, *320*, 156–166. [CrossRef]

20. Scrima, M.; Di Marino, S.; Grimaldi, M.; Campana, F.; Vitiello, G.; Piotto, S.P.; D’Errico, G.; D’Ursi, A.M.
    Structural features of the C8 antiviral peptide in a membrane-mimicking environment. *BBA Biomembr.* **2014**, *1838*,
    1010–1018. [CrossRef]

21. Liu, J.; Deng, Y.; Dey, A.K.; Moore, J.P.; Lu, M. Structure of the HIV-1 gp41 membrane-proximal ectodomain
    region in a putative prefusion conformation. *Biochemistry* **2009**, *48*, 2915–2923. [CrossRef]

22. Buzon, V.; Natrajan, G.; Schibli, D.; Campelo, F.; Kozlov, M.M.; Weissenhorn, W. Crystal structure of HIV-1
    gp41 including both fusion peptide and membrane proximal external regions. *PLoS Pathog.* **2010**, *6*, e1000880.
    [CrossRef] [PubMed]

23. Shi, W.; Bohon, J.; Han, D.; Habte, H.; Qin, Y.; Cho, M.W.; Chance, M.R. Structural characterization of HIV
    GP41 with the membrane proximal external region. *J. Biol. Chem.* **2010**, *285*, 24290–24298. [CrossRef]
    [PubMed]

24. Fu, Q.; Shaik, M.M.; Cai, Y.; Ghantous, F.; Piai, A.; Peng, H.; Rits-Volloch, S.; Liu, Z.; Harrison, S.C.;
    Seaman, M.S.; et al. Structure of the membrane proximal external region of HIV-1 envelope glycoprotein.
    *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E8892–E8899. [CrossRef] [PubMed]

25. D’Errico, G.; D’Ursi, A.M.; Marsh, D. Interaction of a peptide derived from glycoprotein gp36 of feline
    immunodeficiency virus and its lipoylated analogue with phospholipid membranes. *Biochemistry* **2008**, *47*,
    5317–5327. [CrossRef]

26. Desmaris, F.; Lemaire, D.; Ricard-Blum, S.; Chatenet, B.; Forest, E. Structural characterization of the feline-immunodeficiency-virus-envelope glycoprotein 36 ectodomain for the development of new antivirals. *Biochem. J.* **2005**, *389*, 559–567. [CrossRef]

27. D’Ursi, A.M.; Giannecchini, S.; Esposito, C.; Alcaro, M.C.; Sichi, O.; Armenante, M.R.; Carotenuto, A.;
    Papini, A.M.; Bendinelli, M.; Rovero, P. Development of antiviral fusion inhibitors: Short modified peptides
    derived from the transmembrane glycoprotein of feline immunodeficiency virus. *ChemBioChem* **2006**, *7*,
    774–779. [CrossRef]

28. D’Ursi, A.M.; Giannecchini, S.; Di Fenza, A.; Esposito, C.; Armenante, M.R.; Carotenuto, A.; Bendinelli, M.;
    Rovero, P. Retroinverso analogue of the antiviral octapeptide C8 inhibits feline immunodeficiency virus in
    serum. *J. Med. Chem.* **2003**, *46*, 1807–1810. [CrossRef]
29. Giannecchini, S.; D’Ursi, A.M.; Esposito, C.; Scrima, M.; Zabogli, E.; Freer, G.; Rovero, P.; Bendinelli, M. Antibodies generated in cats by a lipopeptide reproducing the membrane-proximal external region of the feline immunodeficiency virus transmembrane enhance virus infectivity. *Clin. Vaccine Immunol.* 2007, 14, 944–951. [CrossRef]  
30. Esposito, C.; D’Errico, G.; Armenante, M.R.; Giannecchini, S.; Bendinelli, M.; Rovero, P.; Anna, M. Physicochemical characterization of a peptide deriving from the glycoprotein gp36 of the feline immunodeficiency virus and its lipoylated analogue in micellar systems. *BBA-Biomembranes* 2006, 1758, 1653–1661. [CrossRef]  
31. Merlino, A.; Vitiello, G.; Grimaldi, M.; Sica, F.; Busi, E.; Basosi, R.; D’Ursi, A.M.; Fragnetto, G.; Paduano, L.; D’Errico, G. Destabilization of lipid membranes by a peptide derived from glycoprotein gp36 of feline immunodeficiency virus: A combined molecular dynamics/experimental study. *J. Phys. Chem. B* 2011, 116, 401–412. [CrossRef]  
32. Giannecchini, S.; Alcaro, M.C.; Isola, P.; Sichi, O.; Pistello, M.; Papini, A.M.; Rovero, P.; Bendinelli, M. Feline immunodeficiency virus plasma load reduction by a retroinverso octapeptide reproducing the Trp-rich motif of the transmembrane glycoprotein. *Antivir. Ther.* 2005, 10, 671–680. [PubMed]  
33. Oliva, R.; Del Vecchio, P.; Stellato, M.I.; D’Ursi, A.M.; D’Errico, G.; Paduano, L.; Petraccone, L. A thermodynamic signature of lipid segregation in biomembranes induced by a short peptide derived from glycoprotein gp36 of feline immunodeficiency virus. *BBA Biomembr.* 2015, 1848, 510–517. [CrossRef] [PubMed]  
34. Pandey, S.; Alcaro, M.C.; Scrima, M.; Peroni, E.; Paolini, I.; Di Marino, S.; Barbetti, F.; Carotenuto, A.; Novellino, E.; Papini, A.M.; et al. Designed glucopeptides mimetics of myelin protein epitopes as synthetic probes for the detection of autoantibodies, biomarkers of multiple sclerosis. *J. Med. Chem.* 2012, 55, 10437–10447. [CrossRef] [PubMed]  
35. Grimaldi, M.; Stillitano, I.; Amodio, G.; Santoro, A.; Buonocore, M.; Molteno, O.; Remondelli, P.; D’Ursi, A.M. Structural basis of antiviral activity of peptides from MPER of FIV gp36. *PLoS ONE* 2018, 13, e0204042. [CrossRef] [PubMed]  
36. Scott, R.E.; Perkins, R.; Zschunke, M.; Hoerl, B.; Maercklein, P. Plasma membrane vesiculation in 3T3 and SV3T3 cells. I. Morphological and biochemical characterization. *J. Cell Sci.* 1979, 35, 229–243.  
37. Del Piccolo, N.; Placone, J.; He, L.; Agudelo, S.C.; Hristova, K. Production of plasma membrane vesicles with chloride salts and their utility as a cell membrane mimetic for biophysical characterization of membrane protein interactions. *Anal. Chem.* 2012, 84, 8650–8655. [CrossRef]  
38. Scott, R.E. Plasma membrane vesiculation: A new technique for isolation of plasma membranes. *Science* 1976, 194, 743–745. [CrossRef]  
39. Scott, R.E.; Maercklein, P.B. Plasma membrane vesiculation in 3T3 and SV3T3 cells. II. Factors affecting the process of vesiculation. *J. Cell Sci.* 1979, 35, 245–252.  
40. Mannhold, R.; Kubinyi, H.; Folkes, G.; Zerbe, O. *BioNMR in Drug Research*; Wiley-VCH: Zurich, Switzerland, 2006; Volume 16.  
41. Zerbe, O. *BioNMR in Drug Research Methods and Principles in Medicinal Chemistry*; Wiley-VCH: Zurich, Switzerland, 2003.  
42. Whitmore, L.; Wallace, B.A. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. *Nucleic Acids Res.* 2004, 32, W668–W673. [CrossRef]  
43. Weller, K.; Lauber, S.; Lerch, M.; Renaud, A.; Merkle, H.P.; Zerbe, O. Biophysical and biological studies of end-group-modified derivatives of Pep-1. *Biochemistry* 2005, 44, 15799–15811. [CrossRef]  
44. Goddard, T.; Kneller, D. SPARKY 3. Ph.D. Thesis, University of California, San Francisco, CA, USA, 2004.  
45. Wüthrich, K. NMR with Proteins and Nucleic Acids. *Europhys. News* 1986, 17, 11–13. [CrossRef]  
46. Cavanagh, J.; Fairbrother, W.J.; Palmer, A.G., III; Skelton, N.J. *Protein NMR Spectroscopy: Principles and Practice*; Elsevier: Amsterdam, The Netherlands, 1995.  
47. Clore, G.M.; Gronenborn, A.M. *NMR of Proteins*; Macmillan International Higher Education: New York, NY, USA, 1993.  
48. Wishart, D.S.; Sykes, B.D. The 13 C chemical-shift index: A simple method for the identification of protein secondary structure using 13C chemical-shift data. *J. Biomol. NMR* 1994, 4, 171–180. [CrossRef] [PubMed]  
49. Kjaergaard, M.; Brander, S.; Poulsen, F.M. Random coil chemical shift for intrinsically disordered proteins: Effects of temperature and pH. *J. Biomol. NMR* 2011, 49, 139–149. [CrossRef]
50. Shen, Y.; Delaglio, F.; Cornilescu, G.; Bax, A. TALOS+: A hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. J. Biomol. NMR 2009, 44, 213–223. [CrossRef]

51. Guntert, P. Automated NMR structure calculation with CYANA. Methods Mol. Biol. 2004, 278, 353–378.

52. Dongre, R.; Folkers, G.E.; Gualerzi, C.O.; Boelens, R.; Wienk, H. A model for the interaction of the G3-subdomain of Geobacillus stearothermophilus IF2 with the 30S ribosomal subunit. Protein Sci. 2016, 25, 1722–1733. [CrossRef]

53. Hutchinson, E.G.; Thornton, J.M. PROMOTIF-A program to identify and analyze structural motifs in proteins. Protein Sci. 1996, 5, 212–220. [CrossRef] [PubMed]

54. Metcalfe, E.E.; Zamoon, J.; Thomas, D.D.; Veglia, G. 1H NMR spectroscopy. Biochim. Biophys. Acta BBA Biomembr. 2013, 1823, 864–876. [CrossRef] [PubMed]

55. de Jesus, A.J.; Allen, T.W. The role of tryptophan side chains in membrane protein anchoring and hydrophobic mismatch. BBA Biomembr. 2018, 1832, 1095–1108. [CrossRef] [PubMed]

56. Sun, Z.-Y.J.; Cheng, Y.; Kim, M.; Song, L.; Choi, J.; Kudahl, U.J.; Brusic, V.; Chowdhury, B.; Yu, L.; Seaman, M.S. Disruption of helix-capping residues 671 and 674 reveals a role in HIV-1 entry for a specialized hinge segment of the membrane proximal external region of gp41. J. Mol. Biol. 2014, 426, 1095–1108. [CrossRef] [PubMed]

57. Reardon, P.N.; Sage, H.; Dennison, S.M.; Martin, J.W.; Donald, B.R.; Alam, S.M.; Haynes, B.F.; Spicer, L.D. Structure of an HIV-1–neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer. Proc. Natl. Acad. Sci. USA 2014, 111, 1391–1396. [CrossRef] [PubMed]

58. Sun, Z.-Y.J.; Oh, K.J.; Kim, M.; Yu, J.; Brusic, V.; Song, L.; Qiao, Z.; Wang, J.-H.; Wagner, G.; Reinherz, E.L. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 2008, 28, 52–63. [CrossRef] [PubMed]

59. Kwon, B.; Lee, M.; Waring, A.; Hong, M. Oligomeric structure and three-dimensional fold of the HIV gp41 membrane–proximal external region and transmembrane domain in phospholipid bilayers. J. Am. Chem. Soc. 2018, 140, 8246–8259. [CrossRef] [PubMed]

60. Lee, J.; Nyenhuis, D.A.; Nelson, E.A.; Cafiso, D.S.; Tamm, L.K. Structure of the Ebola virus envelope protein MPER/TM domain and its interaction with the fusion loop explains their fusion activity. Proc. Natl. Acad. Sci. USA 2017, 114, E7987–E7996. [CrossRef] [PubMed]

61. Kuliopulos, A.; Walsh, C.T. Production, purification, and cleavage of tandem repeats of recombinant peptides. J. Am. Chem. Soc. 1994, 116, 4599–4607. [CrossRef]

62. Maniatis, T. Molecular cloning. In Molecular cloning. In Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, USA, 1989.

63. Rodriguez, J.C.; Wong, L.; Jennings, P.A. The solvent in CNBr cleavage reactions determines the fragmentation efficiency of ketosteroid isomerase fusion proteins used in the production of recombinant peptides. Protein Expr. Purif. 2003, 28, 224–231. [CrossRef]

64. Pellegrini, M.; Mierke, D.F. Structural characterization of peptide hormone/receptor interactions by NMR spectroscopy. Pept. Sci. 1999, 31, 208–220. [CrossRef]

65. DeLano, W.L. Pymol: An open-source molecular graphics tool. CCP4 Newsl. Protein Crystallogr. 2002, 40, 82–92.

66. Tedeschi, A.; Franco, L.; Ruzzi, M.; Paduano, L.; Corvaja, C.; D’Errico, G. Micellar aggregation of alkyltrimethylammonium bromide surfactants studied by electron paramagnetic resonance of an anionic nitroxide. Phys. Chem. Chem. Phys. 2003, 5, 4204–4209. [CrossRef]

67. Molteno, O.; Remondelli, P.; Amadio, G. The Mitochondria-Endoplasmic Reticulum Contacts and their critical role in ageing and age-associated diseases. Front. Cell Dev. Biol. 2019, 7, 172. [CrossRef] [PubMed]

68. Vitiello, G.; Falanga, A.; Petruk, A.A.; Merlino, A.; Fragnetto, G.; Paduano, L.; Galdiero, S.; D’Errico, G. Fusion of raft-like lipid bilayers operated by a membrane-tropic domain of the HSV-type I glycoprotein gH occurs through a cholesterol-dependent mechanism. Soft Matter 2015, 11, 3003–3016. [CrossRef] [PubMed]

69. Caggiano, R.; Cattaneo, F.; Molteno, O.; Esposito, G.; Perrino, C.; Trimmarchi, B.; Ammendola, R.; Faraonio, R. miR-128 is implicated in stress responses by targeting MAFG in skeletal muscle cells. Oxid. Med. Cell. Longev. 2017, 2017, 9308310. [CrossRef] [PubMed]
71. Amodio, G.; Moltedo, O.; Fasano, D.; Zerillo, L.; Oliveti, M.; Di Pietro, P.; Faraonio, R.; Barone, P.; Pellecchia, M.T.; De Rosa, A. PERK-mediated unfolded protein response activation and oxidative stress in PARK20 fibroblasts. Front. Neurosci. 2019, 13, 673. [CrossRef]

72. Fasano, D.; Parisi, S.; Pierantoni, G.M.; De Rosa, A.; Picillo, M.; Amodio, G.; Pellecchia, M.T.; Barone, P.; Moltedo, O.; Bonifati, V.; et al. Alteration of endosomal trafficking is associated with early-onset parkinsonism caused by SYNJ1 mutations. Cell Death Dis. 2018, 9, 385. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).